Greenwich LifeSciences (Greenwich LifeSciences) ROCE % : -145.87% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Greenwich LifeSciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -145.87%.

Greenwich LifeSciences ROCE % Historical Data

The historical data trend for Greenwich LifeSciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenwich LifeSciences ROCE % Chart

Greenwich LifeSciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-14.18

-16.88

-40.15

-93.68

Greenwich LifeSciences Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-80.91	-72.01	-62.62	-102.68	-145.87

Greenwich LifeSciences ROCE % Calculation

Greenwich LifeSciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-9.328	/	( ( (13.477 - 0.263)	+	(6.995 - 0.294) )	/ 2 )
	=	-9.328	/	( (13.214	+	6.701)	/ 2 )
	=	-9.328	/	9.9575
	=	-93.68 %

Greenwich LifeSciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-11.344	/	( ( (9.15 - 0.297)	+	(6.995 - 0.294) )	/ 2 )
	=	-11.344	/	( ( 8.853	+	6.701 )	/ 2 )
	=	-11.344	/	7.777
	=	-145.87 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Greenwich LifeSciences (NAS:GLSI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Greenwich LifeSciences ROCE % Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477

Website

https://www.greenwichlifesciences.com

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.

Executives

Snehal Patel	director, officer: CHIEF EXECUTIVE OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson	officer: VPC AND REGULATORY AFFAIRS	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty	director, officer: CHIEF MEDICAL OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams	director	2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel	10 percent owner	3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel	10 percent owner	50726 LAKESIDE DRIVE, GRANGER IN 46530